company · 8 records
Dr Reddy's Laboratories
HT Evening Brief: Tata Sons Reappoints Chandrasekaran and Russia Sanctions Impact
This news summary covers international sanctions, corporate leadership changes at Tata Sons, political news, a legal case involving Travis Kelce, and sports venue disputes.
Dr Reddy’s bags exclusive distribution rights of Takeda’s dengue vaccine QDENGA
Takeda Pharmaceutical has signed an exclusive distribution agreement with Dr. Reddy's Laboratories to launch the dengue vaccine QDENGA in India.
India to receive its first dengue vaccine by 2027
India will receive its first dengue vaccine, Qdenga, in the first half of 2027 following a partnership between Dr. Reddy's Laboratories and Takeda Pharmaceutical.
Dengue vaccine to launch in India next year
Takeda's dengue vaccine, QDENGA, is expected to launch in India within the first six months of 2027.
Dr. Reddy’s Laboratories launches Nivorz in India
Dr. Reddy’s Laboratories has launched a nivolumab biosimilar named Nivorz in India.
India orders tighter surveillance of pharmaceutical supply chains after Interpol alert
India's drug regulator ordered state authorities to tighten surveillance of pharmaceutical supply chains after an Interpol alert flagged a counterfeit semaglutide batch.
Indian stock markets decline following US tariff proposal on generic drugs
Indian stock markets fell sharply after Donald Trump announced plans to impose tariffs of up to 200% on imported generic drugs, dragging Sensex and Nifty down with pharmaceutical stocks hit hardest.
Trump announces phased tariff increases on imported generic medicines
President Donald Trump announced a phased tariff plan on imported generic medicines that will keep duties at zero for two years before rising to 100% and then 200% to push pharmaceutical production back to the United States, with major implications for Indian drug exporters.